104 results about "Guanosine" patented technology

The purpose of the present invention is to provide a novel beer-flavored fermented beverage in which the purine concentration is reduced and the deterioration in flavor due to the reduction in purine concentration is improved. The present invention provides a beer-flavored fermented beverage having a purine concentration of 35,000 ppb or less, an adenosine concentration of 15,000 ppb or less, or a guanosine concentration of 56,000 ppb or less, wherein the 5-methylfurfural concentration is 10 ppb or more.

The invention relates to the technical field of dye separation, and discloses a loose nanofiltration membrane and a preparation method and application thereof, the loose nanofiltration membrane comprises a porous support membrane, and a polyesteramide separation layer formed on the porous support membrane through one-step interfacial polymerization of nucleoside monomers and multi-acyl chloride monomers. The nucleoside monomer is one or more than two of adenosine, guanosine and cytidine nucleoside. The nucleoside monomer with a long-chain structure, a branched-chain structure, a rigid twisted structure and a plurality of hydrophilic reaction sites is selected as an interfacial polymerization water-phase monomer, so that the loose nanofiltration membrane is endowed with excellent permeation and separation performance. The membrane has a high rejection rate on dye molecules such as Congo red and methyl blue, also has high water permeability and extremely high dye / inorganic salt separation selectivity, and shows good application potential in the aspects of dye production and purification and dye wastewater recovery.

This invention relates to a potassium ion-responsive hydrogel based on iminoboronic ester bonds, its preparation method, and its applications. The hydrogel is prepared using guanosine, 2-formylphenylboronic acid, and polyoxyethylenediamine. The diol of guanosine forms a borate ester bond with 2-formylphenylboronic acid, and the primary amine in the polyoxyethylenediamine forms an imino group with the aldehyde group of 2-formylphenylboronic acid. The bases of guanosine form a G-quadruplex under the influence of potassium ions. The hydrogel has a porous network structure. The preparation method is as follows: A mixed aqueous solution of guanosine, 2-formylphenylboronic acid, and polyoxyethylenediamine is heated to boiling to obtain a clear solution. After cooling, the solution is mixed with a potassium ion solution to prepare the potassium ion-responsive hydrogel based on iminoboronic ester bonds. Compared with the prior art, the hydrogel prepared by this invention exhibits both temperature and potassium ion responsive characteristics.

The present disclosure relates generally to (CRISPR) RNA (crRNA) for the precision silencing of transcripts. In some embodiments, the crRNA are enriched for guanosine (G) nucleotides at key spacer positions, which is useful in enhancing the silencing efficacy of otherwise inefficient crRNA, thereby expanding the targeting spectrum of Cas13 endonucleases, e.g., Cas13b and Cas13d. In other embodiments, the crRNA comprise a spacer sequence having at least one nucleotide mismatch relative to the target RNA sequence, wherein the target RNA sequence is a wild-type transcript and / or a variant transcript (e.g., a transcript comprising a single nucleotide variant (SNV)). The present disclosure also provides RNA editing systems comprising the crRNA described herein in complex a Cas13 effector protein and a target RNA sequence, methods for the selective targeting of transcripts encoding proteins that are difficult to target, or are not amenable to pharmacological targeting, e.g., oncogenic fusion transcripts or oncogenic transcripts comprising single nucleotide variant(s), and methods for the design and selection of potent crRNA.

This application discloses a cyclic GMP-AMP synthase mutant. Compared to the wild-type cyclic GMP-AMP synthase shown in SEQ ID NO.1, the amino acid sequence of the cyclic GMP-AMP synthase mutant has any one of the following mutations: L377M or H437T / S434T. Specifically, the amino acid sequence of the L377M mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.4, and the amino acid sequence of the H437T / S434T mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.9. The cGAS mutant of this application exhibits four times the activity of the wild-type. The preparation method uses readily available and economical raw materials, is simple to operate, environmentally friendly, and pollution-free, with high synthesis efficiency, making it suitable for industrial development.

The invention relates to a novel modified trinucleotide capped derivative and mRNA introduced with the capped derivative, a methylene bridged heterocyclic compound and a derivative of aryl methyl are respectively introduced at the N7 position of 5 '-terminal guanosine base, and the efficiency is superior to that of a capped substance used in an existing mRNA vaccine; therefore, the present invention can be effectively used in the fields of development of mRNA vaccines and development of various mRNA-based therapeutic agents.

A method for increasing or improving nitric oxide signals or levels, the method comprising: administering a composition to a subject, the composition comprising: arginine or a pharmaceutically acceptable salt, ester, or derivative thereof; and tetrahydrocurcumin and / or β-aminoisobutyric acid or a pharmaceutically acceptable salt or ester thereof. The method and the composition can be used to increase, improve, or enhance nitric oxide signals or levels, inhibit nitric oxide decomposition, and increase or enhance nitrous acid and / or cyclic guanosine monophosphate levels, and can improve fatigue resistance or enhance muscle strength, maintain or improve cardiovascular health, maintain or improve vascular function and structure, inhibit or mitigate endothelial cell damage, or mitigate insufficient blood flow.

The invention belongs to the technical field of biological medicines, and particularly relates to a multifunctional peptide and application thereof in anti-inflammatory, antibacterial, mucous membrane repair and intestinal secretion promotion. Specifically, the invention designs a polypeptide and an analogue which have guanylate cyclase C receptor (GUCY2C) agonist activity and anti-inflammatory, antibacterial and mucous membrane repair functions at the same time. The polypeptide can be combined with GUCY2C, stimulate generation of cyclic guanosine monophosphate (cGMP) in cells, promote intestinal fluid secretion, inhibit release of proinflammatory factors, relieve inflammatory response, promote repair of intestinal injury mucosa, inhibit growth of opportunistic pathogenic bacteria and accelerate intestinal homeostasis recovery after intestinal preparation. The composition can effectively promote intestinal tract cleaning, does not cause intestinal inflammation and mucosal lesion, has no hemolytic toxicity and cytotoxicity, is high in safety, and has a good clinical application prospect.

An oligonucleotide molecule has 10 to 50 nucleotides that include at least one G-quartet forming motif having 10 to 20 nucleotide residues. At least 60% of the residues of the G-quartet forming motif are guanosine or deoxyguanosine residues. The oligonucleotide molecule inhibits tumor growth and / or viral or bacterial replication and / or exerts anti-inflammatory effects in mammalian cells.

The present application relates to the cosmetic technical field, specifically to a composition containing guanosine component and capable of promoting scalp epidermal cell regeneration and a preparation method, which comprises the following raw material components in percentage by weight: 0.5-20% of surfactant AES, 0.5-10% of biota extract, 0.5-12% of pueraria extract, 0.5-12% of ginger extract, 0.5-10% of ginsenoside extract, 0.5-10% of hydrolyzed corn starch, 0.2-2% of tetraphosphoric acid di-guanosine (GP4G), 1-10% of base liquid, 1-5% of humectant, 0.1-2% of thickening agent, 0.01-1.0% of preservative, and the rest is deionized water. The formula has no irritation, is mild, can significantly increase hair growth and hair volume, increase hair follicle hair retention, inhibit hair loss, promote the re-development of hair follicles, has very significant dandruff and itching relieving functions, and has a simple operation process, and is suitable for industrial manufacturing.

This invention relates to the fields of environmental chemistry and biological sample analysis, specifically to an analytical method for detecting oxidative stress biomarkers in urine. Based on liquid chromatography-tandem mass spectrometry (LC-MS / MS), this invention provides an analytical method for the simultaneous detection of dityrosine, 8-hydroxyguanosine, 8-hydroxydeoxyguanosine, and 4-hydroxynonenal mercaptouric acid in human urine. This method achieves effective purification of urine samples through specific pretreatment, reducing matrix effects, and, combined with specific LC parameters, enables the simultaneous detection of four oxidative stress biomarkers. This method exhibits good selectivity, high sensitivity, and fast detection speed, solving the current problem of the inability to simultaneously determine polar and nonpolar components. It includes a more comprehensive and rational list of oxidative stress biomarkers, better reflecting the body's oxidative stress damage.

The invention relates to the technical field of biological medicine, in particular to guanosine oxidation piRNA-014733, antisense nucleotide and application of the guanosine oxidation piRNA-014733 and the antisense nucleotide. The guanosine oxidation piRNA is named as o8G piRNA-014733, the guanosine oxidation piRNA is related to the regulation and control of myocardial ischemia reperfusion injury and myocardial cell ferroptosis, and the nucleotide sequence of the o8G piRNA-014733 gene is shown as SEQ ID NO. 1. The antisense nucleotide sequence of the o8G piRNA-014733 is as shown in SEQ ID NO. 2, and the antisense nucleotide sequence is as shown in SEQ ID NO. The expression of the o8G piRNA-014733 provided by the invention in heart tissues suffering from ischemia reperfusion injury and myocardial cells suffering from ferroptosis is remarkably up-regulated, and the o8G piRNA-014733 antisense nucleotide provided by the invention can be used for down-regulating the expression level of the o8G piRNA-014733 and inhibiting the ferroptosis of the myocardial cells.

The present disclosure generally relates to the use of linear nucleic acid primers for the amplification of a target nucleic acid sequence, for example, in a cell-free environment. In some embodiments, compositions of the linear nucleic acid primers are provided. For example, in some embodiments, the linear nucleic acid primers comprise a guanosine or a cytidine at 3′ terminal end. In some embodiments, the linear nucleic acid primers have been optimized to prevent primer-homodimer and / or hairpin formation and to exclude cumbersome codon sequences. In some embodiments, methods are provided for the amplification of a DNA template fragment using the linear nucleic acid primers. Thus, in some cases, the use of the nucleic acid primers, as described herein, may allow for the reduction in amplification of non-specific hybridization events while allowing for the amplification of the target nucleic acid sequence.

The invention relates to a preparation method of a cyclic guanylic acid (Guanosine 3 ', 5'-cyclic guanylic acid, cGMP) detection kit based on a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a cyclic guanylic acid (Guanosine 3 ', 5'-cyclic guanylic acid, cGMP) detection kit based on a chemiluminescence immunoassay technology. Cyclic guanylate is small in molecular weight and poor in immunogenicity. When a corresponding antibody is prepared, a proper isomer and a derivative site need to be selected firstly, and a derivative hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a cyclic guanylic acid hapten, a cyclic guanylic acid complete antigen, preparation of an anti-cyclic guanylic acid antibody, a method for measuring the concentration of cyclic guanylic acid, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a cyclic guanylate derivative. The cyclic guanylate derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

This invention discloses *Pediococcus lactis* TC-4, which simultaneously degrades nucleosides, purines, and uric acid, and its applications. *Pediococcus lactis* ( Pediococcus acidilactici This invention relates to *Pediococcus lactis* TC-4, with accession number GDMCC No: 67936. *Pediococcus lactis* TC-4 of this invention can efficiently degrade three nucleosides (guanosine, adenosine, and inosine), three purines (guanine, xanthine, and hypoxanthine), and uric acid in vitro. *Pediococcus lactis* TC-4 of this invention can effectively reduce serum uric acid levels in broiler chickens, alleviating and treating hyperuricemia. Compared with traditional chemical drugs for treating hyperuricemia and / or gout, this invention has no toxic side effects on the ecological environment, no residue risk, and is green and safe. This invention has been confirmed at multiple levels, including genetic and animal studies, to have no potential harm to humans, demonstrating its advantages of safety and high efficiency.

The application discloses a food-borne pathogenic bacteria detection method based on composite nanomaterials and belongs to the technical field of food safety detection. The method is characterized by the following steps: synthesizing cerium-based nanomaterial DPA-Ce-GMP with enzyme-like activity based on Ce(CH3COO)3, guanosine-5'-monophosphate disodium (GMP) and 2,6-pyridine dicarboxylic acid (DPA); taking Prussian blue as a carrier; using vancomycin to identify gram-positive bacteria; and constructing a composite nanomaterial PB@DPA-Ce-GMP@Van with targeting and oxidase characteristics, namely PCV. The PCV can be precisely adsorbed on the surface of gram-positive bacteria to form a PCV / gram-positive bacteria composite. The residual PCV in the supernatant after centrifugation can quench the fluorescence of scopolamine (SC) and increase the fluorescence intensity of fluorescent red dye (AR) at the same time. The fluorescence intensity ratio (SC / AR) is used as a detection signal output. The application realizes a composite nanometer platform for rapid detection of bacteria, has high sensitivity and strong anti-interference ability, and has a detection range of 10 1 ~ 10 7 CFU / mL and a detection limit of 5 CFU / mL.

This invention relates to the field of probiotics technology, specifically to a Bifidobacterium adolescentis BN18 and its postbiotics for lowering uric acid and improving gout symptoms, and their applications. The Bifidobacterium adolescentis BN18 can promote the degradation of inosine and guanosine, thereby reducing uric acid levels in the blood. The postbiotics for Bifidobacterium adolescentis BN18 are made from carefully selected raw materials such as carrots, winter melon, blueberries, apples, lemons, and fructooligosaccharides as the core components of the composition. Through deep fermentation with BN18, the resulting postbiotics not only reduce the activity of xanthine oxidase and lower uric acid levels in the blood, thus promoting uric acid reduction, but also significantly enhance their antioxidant properties, reducing inflammatory responses, lowering inflammation levels, alleviating joint pain, and improving gout symptoms.

The invention discloses an oral ulcer intelligent microneedle patch based on guanosine vesicle slow release and a preparation method thereof, and relates to the technical field of drug research and development, and the key points of the technical scheme are that the intelligent microneedle patch can penetrate through an oral ulcer pseudo membrane to realize targeted delivery of drugs; long-acting slow release of a therapeutic drug (guanosine) is realized through the guanosine vesicles, and continuous anti-inflammatory and tissue repair effects are achieved; the guanosine is a natural nucleoside and is an important construction unit of the supramolecular hydrogel. Therefore, more diversified supramolecular hydrogels based on guanosine and derivatives thereof also appear in continuous modification. The guanosine borate supramolecular hydrogel is used as a nano-scaffold with good biocompatibility and stimulation responsiveness, and has the potential of conveying various therapeutic drugs in the aspect of drug conveying. The intelligent microneedle patch can monitor a plurality of key physiological parameters of an ulcer microenvironment in real time, and diagnosis and treatment integration is achieved.

Cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (cGAS) is an enzyme sensor of double-stranded DNA (dsDNA) that serves to trigger activation of the cGAS-stimulator of interferon genes (STING) pathway. The inhibition of cGAS with Cladophorol A is described herein.

The present invention discloses a method for preparing 2'-deoxyguanosine, guanosine and a composition thereof, and uses thereof, which belong to the technical field of controlling pathogenic microorganisms, specifically, the use of 2'-deoxyguanosine and guanosine in inhibiting Vibrio parahaemolyticus in marine fish farming, the use of 2'-deoxyguanosine and guanosine in anti-plant viruses, and the use of 2'-deoxyguanosine and guanosine in improving the content of 2'-deoxyguanosine, guanosine and salicylic acid in plants. The present invention provides a composition containing 2'-deoxyguanosine and guanosine, and a method for extracting 2'-deoxyguanosine and guanosine from Paecilomyces variotii SJ1 fungus. The present invention has found that 2'-deoxyguanosine and guanosine have an effect of controlling pathogenic microorganisms, in particular, a remarkable anti-plant virus effect, and can also improve the contents of 2'-deoxyguanosine, guanosine, and salicylic acid in plants.

The invention discloses square polymer nanoparticles based on hydrogen-bond interaction as well as a preparation method and application of the square polymer nanoparticles. The square polymer nanoparticles are formed by self-assembly of a guanosine-polyethylene glycol polymer in water through hydrogen bond interaction, wherein the guanosine-polyethylene glycol polymer is obtained by copolymerization of a guanosine-double bond monomer and a polyethylene glycol monomer through a reversible addition-fragmentation chain transfer reaction. The square polymer nanoparticles have the capacity of fixing potassium ions, can destroy the steady state of intracellular potassium ions and influence the cell activity when being delivered into tumor cells, and have potential application prospects in preparation of tumor treatment drugs.

The purpose of the present invention is to provide a novel beer-flavored fermented beverage in which the purine concentration is reduced and deterioration of flavor due to the reduction of the concentration of purine is improved. The present invention provides a beer-flavored fermented beverage having a purine concentration of 35,000 ppb or less, an adenosine concentration of 15,000 ppb or less, or a guanosine concentration of 56,000 ppb or less, wherein the 2-acetylpyrrole concentration is 20 ppb or more.

Provided is a method for producing a ribose phosphate compound, the method comprising hydrolyzing a compound represented by general formula (3) in the presence of an acidic compound by a pressurized flow reaction, thereby producing a ribose phosphate compound represented by general formula (1). R1 represents a hydrogen atom, a hydroxy group, or OR11, and R11 represents a group represented by general formula (2). R2 and R3 each represent a hydrogen atom or a group represented by general formula (2). The two R12 each represent a hydrogen atom or an alkali metal ion. * indicates a bonding part with an oxygen atom. R5 represents an adenyl group, a guanyl group, a cytosyl group, a uracil group, or a thyminyl group.　The compounds represented by general formulae (1) and (3) each have at least one group represented by general formula (2) per molecule.

Provided are a recombinant Escherichia coli for producing D-mannose, and a preparation method therefor, belonging to the field of food chemical engineering. A recombinant strain is provided, which is a recombinant strain obtained by performing the following modifications A) and B) in Escherichia coli; A) inhibiting or reducing expression of the pfkA gene, pfkB gene, zwf gene and / or lpxM gene in the Escherichia coli; B) increasing the expression of a D-mannose-6-phosphate isomerase encoding gene, a phosphomannomutase encoding gene, a phosphomannose guanylyltransferase encoding gene, and a GDP-mannose hydrolase encoding gene in the Escherichia coli. The recombinant strain uses D-glucose, glycerol, etc. as carbon sources to support microbial growth, and can also grow by utilizing mixed carbon sources containing the described carbon source components. After microbial growth reaches a certain biomass, D-glucose is used as a raw material to synthesize D-mannose.

The present invention relates to efficient processes useful in the preparation of fluorinated nucleosides, such as (2S,3R,4S,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3-fluoro-4-hydroxy-2-(mercaptomethyl)tetrahydrofuran-3-yl dihydrogen phosphate, also known as 3′-fluoro-thio-guanosine monophosphate or 3′-F-thio-GMP. Such fluorinated nucleosides may be useful as a biologically active compound and or as an intermediate for the synthesis of more complex biologically active compounds. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation. (I)

The invention belongs to the technical field of enzyme engineering, and particularly relates to a guanylate kinase mutant with improved thermal stability and application and a product thereof. Aiming at the defects that wild guanylate kinase is insufficient in thermal stability and easy to inactivate in reaction, mutants (A24Q, S75P, K146P and L172I) are obtained by site-directed mutagenesis modification based on a wild guanylate kinase sequence. The mutant is replaced by specific amino acid residues, so that the thermal stability is remarkably improved, meanwhile, good catalytic activity is kept, wider temperature conditions can be tolerated, and the effective action time of enzyme is prolonged. The mutant can efficiently catalyze a phosphate group transfer reaction of guanylic acid and adenosine triphosphate, and is suitable for enzymatic synthesis of nucleoside compounds such as guanosine diphosphate. The application of the enzyme source can reduce the use amount and supplement frequency of enzyme preparations, reduce the production cost, improve the product yield and quality, and provide reliable enzyme source support for the industrial efficient production of nucleoside products.

The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′5′-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.

Disclosed herein are antibodies, or antigen-binding fragments thereof, that bind to guanylate cyclase C (GUCY2C), multispecific antibodies comprising the same, and methods of treating cancer using the same.

The application provides a uridine monophosphate specific glycoside hydrolase and application thereof in biosynthetic synthesis of pseudouridine. Nmygdh The function of the gene is verified by in-vitro enzyme activity experiment Nmygdh The recombinant protein has broad-spectrum and high-efficiency catalytic activity, and can efficiently catalyze the hydrolysis of glycosidic bonds in various nucleotides, such as uridine monophosphate (UMP), guanosine monophosphate (GMP), adenosine monophosphate (AMP) and cytidine monophosphate (CMP), and the activity of uridine monophosphate is the strongest. The application uses the protein to efficiently hydrolyze uridine monophosphate to obtain two substrates of pseudouridine, i.e. uracil and 5'-phosphoribose, and realizes the atom-economical and efficient biosynthetic synthesis of pseudouridine by combining the cascade reaction of pseudouridine glycosidase EcPsuG and dephosphorylase EcYjjG.